Acadia Claims Success For Nuplazid In A Broader Psychosis Indication

 
• By Jessica Merrill
Business success concept with target as motivation (3D Rendering) - Illustration
Acadia's pimavanserin trial was stopped early due to efficacy in dementia-related psychosis

More from Neurological

More from Therapeutic Category